AR and prostate cancer: Neuwirt et al. also found a promising mechanistic pathway for inhibiting therapy resistance in prostate cancer relating to CAF-mediated upregulation of cholesterol and steroid biosynthesis, which cause tumor growth and progression while resisting androgen receptor (AR)-targeted therapies.